

Carbon Reduction Plan

Supplier name: IPS Pharma

Publication date: 01/04/2024

Commitment to achieving Net Zero

IPS Pharma is committed to achieving Net Zero emissions by 2050.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

IPS Pharma have baselined calendar year 2023 and therefore publishing baseline and current year emission reporting in tandem. Carbon emissions from calendar year 2024, will be reported in 2025.

Baseline Year: 2023	
Additional Details relating to the Baseline Emissions calculations.	
<i>IPS Pharma have engaged a professional carbon accounting and decarbonisation specialist, Auditel, to help accurately report all required emissions based on activity data and achieve verification standard reporting. The process has highlighted gaps in some historic data within Scope 3 which is being rectified.</i>	
<i>All Scope 1 & 2 calculations use evidenced actual data of either volumetric measures (litres consumed of fuel in vehicles/kg) or kWh in the case of electricity supply and reported against GHG protocol standards.</i>	
<i>Estimates have been used to report the subset of Scope 3 emissions at this stage, while data cleansing and data quality is improved. The report will be update within year, to full GHG protocol standard.</i>	
Baseline year emissions:	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	38.76 tCO₂e
Scope 2	51.15 tCO₂e

Scope 3 (Included Sources)	2,395.56 tCO₂e 3.3 Fuel and Energy related Activities – 4.43 tCO ₂ e Electricity, 4.63 tCO ₂ e Gas, 3.4 Upstream Transport & Distribution – 1,000.00 tCO ₂ e (est.) 3.5 Waste – 1.5 tCO ₂ e (est.) 3.6 Business Travel – 150 tCO ₂ e (est.) 3.7 Employee Commuting (inc. WTT) and homeworking – 35 tCO ₂ e (est.) 3.9 Downstream Transport & Distribution – 1,200.00 tCO ₂ e (est.) Sources included: Upstream Transportation and Distribution, Waste generated in operations, Business Travel, Employee Commuting, Home Working, Downstream Transportation and Distribution
Total Emissions	2,485.47 tCO₂e

Current Emissions Reporting


Reporting Year: 2023	
EMISSIONS	TOTAL (tCO₂e)
Scope 1	38.76 tCO₂e
Scope 2	51.15 tCO₂e
Scope 3 (Included Sources)	2,395.56 tCO₂e 3.3 Fuel and Energy related Activities – 4.43 tCO ₂ e Electricity, 4.63 tCO ₂ e Gas 3.4 Upstream Transport & Distribution – 1,000.00 tCO ₂ e (est.) 3.5 Waste – 1.5 tCO ₂ e (est.) 3.6 Business Travel – 150 tCO ₂ e (est.) 3.7 Employee Commuting (inc. WTT) and homeworking – 35 tCO ₂ e (est.) 3.9 Downstream Transport & Distribution – 1,200.00 tCO ₂ e (est.) Sources included: Upstream Transportation and Distribution, Waste generated in operations, Business Travel, Employee Commuting, Home Working, Downstream Transportation and Distribution
Total Emissions	2,485.47 tCO₂e

Emissions reduction targets

IPS Pharma is currently in the process of developing a comprehensive, verifiable decarbonisation strategy, accompanied by short-term and long-term targets. More details will be released in a future report.

We are committed to reaching Net Zero emissions by 2050 per the requirements of this plan. From our baseline, we will be continuously evaluating carbon reduction initiatives to reduce our emission and working in partnership with suppliers to support indirect emission reduction.

Progress against these targets can be seen in the graph below:



Carbon Reduction Projects

Completed Carbon Reduction Initiatives

The following introductions were made to the business prior to baselining activities but demonstrate IPS Pharma commitment to achieving net zero:

- Introduction of first line virtual meetings where possible, engaging employees to consider environmental awareness
- Comprehensive carbon emissions reports for the businesses operational heating and cooling activities
- Review of petrol and diesel fleet vehicles with transition to hybrid and EV in 2023.
- Adoption of energy efficient LED lighting installed across IPS Pharma UK operations.

We are working towards implementing additional measures, such as:

- • Energy efficiency projects – exploring renewable energy, investigating the installation of Solar PV and/or green electricity. Working with our facilities to optimize assets and reduce energy requirements.
- • Improve our logistics delivery patterns for shipments made into IPS Pharma and outbound sales and/or clinical trials.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

Vish Patani

Vish Patani – Chief Financial Officer, IPS Pharma

Date: 01/04/2024

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>